Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
2.70% $0.0570
America/New_York / 29 des 2023 @ 15:49
FUNDAMENTALS | |
---|---|
MarketCap: | 5.16 mill |
EPS: | -1.990 |
P/E: | -0.0286 |
Earnings Date: | Feb 25, 2024 |
SharesOutstanding: | 90.48 mill |
Avg Daily Volume: | 0.0995 mill |
RATING 2023-12-29 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Neutral | |
P/E: | Neutral | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/21 | 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.0286 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.00x |
Company: PE -0.0286 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.0550 - 0.0590 ( +/- 3.51%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-02-24 | Appelhans Dannielle | Sell | 10 385 | Common Stock |
2023-02-01 | Cagnoni Pablo J | Sell | 8 448 | Common Stock |
2023-01-31 | Appelhans Dannielle | Sell | 7 500 | Restricted Stock Units |
2023-01-31 | Appelhans Dannielle | Buy | 7 500 | Common Stock |
2023-02-01 | Appelhans Dannielle | Sell | 3 878 | Common Stock |
INSIDER POWER |
---|
40.14 |
Last 96 transactions |
Buy: 4 525 378 | Sell: 349 777 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.0570 (2.70% ) |
Volume | 0.756 mill |
Avg. Vol. | 0.0995 mill |
% of Avg. Vol | 759.39 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.